r

Clinical Trials- Lung

 DISEASE SITE  TITLE  PHASE  CONTACT LOCATION 
 NSCLC A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMab in Combination with Tarceva in
Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced or Metastatic Disease
(Genentech OAM4971g)
III  Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 NSCLC A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/
Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer (GENENTECH GO27912)
 II Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 NSCLC Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable
Locally Advanced (Stage IIA, N2+) Non-Small Cell Lung Cancer (RTOG 0839)
 II Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 NSCLC LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutation(s) (BIPI 1200.45)   Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 NSCLC Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients with Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer (Sara Cannon LUN 186)  II/III Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 NSCLC Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC#736511, IND #74019) As Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer (CALGB 30607) III Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
 Lung Early Lung Cancer Detection Using Computed Tomography (I-ELCAP 20090325)   Marlene Watson RN
marlene.watson@nmhs.org
402-354-5831
Nebraska Methodist Hospital
Omaha, NE
NSCLC  "A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with
Completely Resected Stage IB (>/=+4CM)-IIIA Non-Small Cell Lung Cancer (E1505)" 
 III  Marcia Grafe                    402-483-2827 mgrafe@lmep.com  Lincoln Medical Education Partership Lincoln, NE
 NSCLC  "A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous
NSCLC after Definitive Chemoradiation
***Note: IMRT or 4D RT is allowed on this trial. The treating RT facility must have an approved 3D RT Benchmark on file with QARC***. (E6508)" 
 II  Marcia Grafe                    402-483-2827 mgrafe@lmep.com   Nebraska Cancer Research Center, Lincoln Medical Education Partership Lincoln, NE
 NSCLC  "Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019)
as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based
Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer  (C30607)" 
 III  Marcia Grafe                    402-483-2827 mgrafe@lmep.com  Lincoln Medical Education Partership Lincoln, NE
 NSCLC  "Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination
of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non- Squamous NSCLC  (E5508)" 
 III

 Marcia Grafe                    402-483-2827 mgrafe@lmep.com

-------------------------------------------

Good Samaritan – Michaela Sherbeck  michaelasherbeck@catholichealth.net

-----------------------------

Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

 Lincoln Medical Education Partership Lincoln, NE;

Good Samaritan Cancer Center, Kearney, NE;

Missouri Valley Cancer Consortium, Omaha NE

 NSCLC  A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>/=+4CM)-IIIA Non-Small Cell Lung Cancer (E1505)  III

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

-------------------

 Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

------------------------

Good Samaritan – Michaela Sherbeck - michaelasherbeck@catholichealth.net

------------------

Rebecca Hadenfeldt, RN, BSN

RHadenfeldt@sfmc-gi.org

P: 308-398-6783

F: 309-398-3219

 

Nebraska Medical Center, Omaha, NE;

Missouri Valley Cancer Consortium, Omaha, NE;

Good Samaritan Cancer Center, Kearney, NE;

Saint Francis Cancer Treatment Center, Grand Island, NE

 NSCLC  A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous NSCLC after Definitive Chemoradiation (E6508) ***Note:  IMRT or 4D RT is allowed on this trial.  The treating RT facility must have an approved 3D RT Benchmark on file with QARC***.  II

 Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

 Missouri Valley Cancer Consortium, Omaha, NE
 NSCLC  Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer (C30607)  III

 Natasha Wilson, nwilson@mvcc.cc

 402-991-8070 x203

and

Nebraska Cancer Research Center – Kelly Madcharo – kmadcharo@lmep.com

 Missouri Valley Cancer Consortium, Omaha, NE;

Nebraska Cancer Research Center, Lincoln NE

 

NSCLC

 A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer (E3508)  II

 Natasha Wilson, nwilson@mvcc.cc

402-991-8070 x203

--------------------------

Nebraska Cancer Research Center – Kelly Madcharo – 402-483-2827 kmadcharo@lmep.com

-----------------------------------------------

                

 Missouri Valley Cancer Consortium, Omaha, NE;

Nebraska Cancer Research Center, Lincoln NE

 

NSCLC

 Eppley Cancer Center Protocol 339-07 Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer  II

Deborah Meyer, RN, BGS (402) 559-6941 dmeyerk@unmc.edu  or Beth Kos

---------------------------------

Rebecca Hadenfeldt, RN, BSN

RHadenfeldt@sfmc-gi.org

P: 308-398-6783

F: 309-398-3219

 

 

 Nebraska Medical Center, Omaha, NE;

Saint Francis Cancer Treatment Center, Grand Island, NE

 Lung  A Phase lll Trial of Calfactant for Acute Lung Injury (ALI) in Pediatric Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Patients  III  Machelle Zink  Nebraska Medical Center, Omaha, NE
 

NSCLC

  A Randomized, Phase lll Study Comparing Carboplatin/Paclitaxel or CarboPlatin/Paclitaxel/Bevacizumab with or Without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)  (SWOG  0819)  III

 

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

 or Jolene Tijerina

--------------------------

Rebecca Hadenfeldt, RN, BSN

RHadenfeldt@sfmc-gi.org

P: 308-398-6783

F: 309-398-3219

 

 Nebraska Medical Center, Omaha, NE;

Saint Francis Cancer Treatment Center, Grand Island, NE

 

NSCLC

 A Randomized Phase III double Blind Trial Evaluating Selective Cox-2 Inhibition in Cox-2 Expressing Advanced Non-Small Cell Lung Cancer. (CALGB 30801)  

Good Samaritan – Michaela Sherbeck michaelasherbeck@catholichealth.net

 
Good Samaritan Cancer Center, Kearney NE

NSCLC

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)  III  

Deborah Meyer, RN, BGS

 (402) 559-6941

dmeyerk@unmc.edu

or Jolene Tijerina
 Nebraska Medical Center, Omaha, NE
 

NSCLC

A randomized, double-blind, Placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin Alfa administered at 500 ug once every 3 weeks in anemic subjects with advanced stage NSCLC receiving multi-cycle chemotherapy  ( Amgen 20070782)    

Rebecca Hadenfeldt, RN, BSN

RHadenfeldt@sfmc-gi.org

P: 308-398-6783

F: 309-398-3219

 Saint Francis Cancer Treatment Center, Grand Island, NE
 Lung Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer (RTOG 1012)  II  

Good Samaritan – Michaela Sherbeck michaelasherbeck@catholichealth.net

 Good Samaritan Cancer Center

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software